Editas Medicine, Inc. (EDIT)
Stock Price:
$35.32 USD
0.57 (1.64%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $35.54 +0.22 (0.62%) Aug 13, 7:13 PM
Key Info
| Market Cap |
1.94B |
| Revenue (ttm) |
32.60M |
| Net Income (ttm) |
-132.01M |
| Shares Out |
62.27M |
| EPS (ttm) |
-2.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$35.32 |
| Previous Close |
$34.75 |
| Change ($) |
0.57 |
| Change (%) |
1.64% |
| Day's Open |
34.60 |
| Day's Range |
34.52 - 35.57 |
| Day's Volume |
447,426 |
| 52-Week Range |
14.01 - 39.96 |
More Stats
| Market Cap |
1.94B |
| Enterprise Value |
1.37B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
62.27M |
| Float |
60.93M |
| EPS (basic) |
-2.51 |
| EPS (diluted) |
-2.49 |
| FCF / Share |
-1.42 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.40M |
| Short Ratio |
10.09 |
| Short % of Float |
14.20% |
| Beta |
1.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
59.58 |
| PB Ratio |
5.07 |
| Revenue |
32.60M |
| Operating Income |
-151.97M |
| Net Income |
-132.01M |
| Free Cash Flow |
-78.65M |
| Net Cash |
569.92M |
| Net Cash / Share |
10.36 |
| Gross Margin |
-234.23% |
| Operating Margin |
-466.09% |
| Profit Margin |
-404.90% |
| FCF Margin |
-241.23% |
| ROA |
-18.79% |
| ROE |
-42.59% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
5 |
| Overweight |
1 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$41.88*
(18.57% upside)
Low
28.0
Current: $35.32
High
65.0
Target: 41.88
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 20.53 | 31.94 | 13.73 | 6.05 | 1.63 | - |
| Revenue Growth | -35.71% | 132.64% | 126.8% | 271.58% | - | - |
| Gross Profit | 20.53 | 31.94 | 13.73 | 6.05 | 1.63 | - |
| Operating Income | -141 | -114 | -120 | -97.19 | -35.31 | -12.72 |
| Net Income | -134 | -110 | -120 | -97.18 | -72.90 | -13.69 |
| Shares Outstanding | 49.98 | 47.10 | 40.32 | 32.22 | 2.57 | 1.12 |
| Earnings Per Share | -2.68 | -2.33 | -2.98 | -3.02 | -28.55 | -12.46 |
| Operating Cash Flow | -40.67 | -45.71 | -9.42 | -50.25 | -5.44 | -8.66 |
| Capital Expenditures | -6.07 | -4.72 | -2.04 | -3.47 | -1.43 | -1.22 |
| Free Cash Flow | -46.73 | -50.42 | -11.46 | -53.72 | -6.87 | -9.87 |
| Cash & Equivalents | 457 | 369 | 329 | 185 | 143 | 10.62 |
| Total Debt | 29.08 | 32.42 | 40.93 | 45.10 | - | 0.41 |
| Net Cash / Debt | 428 | 337 | 288 | 140 | 143 | 10.21 |
| Assets | 509 | 420 | 373 | 229 | 149 | 12.19 |
| Liabilities | 246 | 184 | 165 | 94.58 | 32.56 | 6.71 |
| Book Value | 262 | 236 | 208 | 135 | -83.11 | -15.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Editas Medicine, Inc. |
| Country |
United States |
| Employees |
208 |
| CEO |
Cynthia L. Collins |
Stock Information
| Ticker Symbol |
EDIT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EDIT |
| IPO Date |
February 3, 2016 |
Description
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.